Welcome to our dedicated page for Solana Company news (Ticker: HSDT), a resource for investors and traders seeking the latest updates and insights on Solana Company stock.
Solana Company (NASDAQ: HSDT) generates news across two distinct but connected areas: its neurotech medical device operations and its Solana-focused digital asset treasury strategy. Company press releases and SEC filings highlight developments in clinical research, regulatory submissions, capital markets transactions, and digital asset management.
On the medical device side, Solana Company describes itself as a neurotech company focused on neurologic deficits using an orally applied technology platform to promote neuroplasticity. News items include announcements of positive clinical data related to the PoNS® device and submissions to the U.S. Food and Drug Administration, such as a 510(k) filing for a stroke-related label expansion.
On the digital asset treasury side, Solana Company reports on its efforts to build and manage a treasury of Solana (SOL) tokens. Recent updates have covered a large private investment in public equity (PIPE) financing, the launch of an at-the-market (ATM) program, the approval of a stock repurchase plan, and partnerships with Pantera Capital and Summer Capital. The company also issues news about its SOL holdings, staking performance, and relationships with staking and custody providers, including Helius, Twinstake, Anchorage Digital Bank, and BitGo.
Investors following HSDT news can expect coverage of quarterly financial results, changes in auditors and board composition, applications affecting its reporting status in Canada, and initiatives such as the planned tokenization of HSDT shares on Superstate’s Opening Bell platform. This news page aggregates these disclosures so readers can review Solana Company’s operational, financial, and treasury-related updates in one place.
Helius Medical Technologies (NASDAQ: HSDT) has submitted a request to the FDA for de novo classification and clearance of its Portable Neuromodulation Stimulator (PoNS) device, aimed at treating gait deficits in Multiple Sclerosis patients. The device was granted Breakthrough Designation on May 7, 2020. Preliminary Q2 2020 revenue is expected to be $0.1 million, down from $0.5 million in Q2 2019, while operating loss is projected at $3.7 million, an improvement from $5.8 million year-over-year. Cash reserves stand at $5.3 million as of June 30, 2020.
Helius Medical Technologies (Nasdaq: HSDT) announced its participation in the Virtual Summer Summit, scheduled from June 9th-12th, 2020. Management will present on June 9th at 4:30 p.m. ET. A live audio webcast will be available on the company's investor relations website, with an archived replay after the conference.
Helius focuses on neurological wellness, developing non-invasive technologies. Its first product, the Portable Neuromodulation Stimulator (PoNS™), targets gait deficits from neurological conditions.
Helius Medical Technologies (NASDAQ: HSDT) announced Breakthrough Designation for its PoNS™ device, aimed at treating gait deficits in Multiple Sclerosis patients. This designation allows expedited development and assessment by the FDA, with the goal of improving patient mobility through a non-drug treatment approach. The PoNS device is currently authorized in Canada and under investigation in the U.S. and other regions. The Breakthrough Devices Program facilitates timely access for critical medical devices while ensuring compliance with regulatory standards.
Helius Medical Technologies (HSDT) reported Q1 2020 financial results revealing a revenue decline to $0.2 million from $0.7 million in Q1 2019, driven primarily by decreased product sales of $191 thousand. The company experienced an operating loss of $4.0 million, a 41% improvement from the previous year. Net loss was $4.8 million, compared to a net income of $1.3 million in Q1 2019. Cash reserves decreased to $4.4 million as of March 31, 2020. Due to uncertainties from the COVID-19 pandemic, the full-year outlook has been withdrawn.
Summary not available.
Summary not available.